Non-Oncology Precision Medicine Market (By Product: Diagnostics, Therapeutics; By Application: Oncology, CNS, Immunology, Respiratory, Infectious Diseases, Neurology, Others; By End-use: Hospitals, Diagnostic Centers, Research & Academic Institutes, Others; By Ecosystem: Applied Sciences, Precision Diagnostics, Precision Therapeutics, Digital Health and Information Technology) - Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2024 – 2034
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Non-Oncology Precision Medicine Market
5.1. COVID-19 Landscape: Non-Oncology Precision Medicine Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Non-Oncology Precision Medicine Market, By Product Type
8.1. Non-Oncology Precision Medicine Market, by Product Type, 2023-2032
8.1.1. Diagnostics
8.1.1.1. Market Revenue and Forecast (2021-2034)
8.1.2. Therapeutics
8.1.2.1. Market Revenue and Forecast (2021-2034)
Chapter 9. Global Non-Oncology Precision Medicine Market, By Application
9.1. Non-Oncology Precision Medicine Market, by Application e, 2023-2032
9.1.1. Oncology
9.1.1.1. Market Revenue and Forecast (2021-2034)
9.1.2. CNS
9.1.2.1. Market Revenue and Forecast (2021-2034)
9.1.3. Immunology
9.1.3.1. Market Revenue and Forecast (2021-2034)
9.1.4. Respiratory
9.1.4.1. Market Revenue and Forecast (2021-2034)
9.1.5. Infectious Diseases
9.1.5.1. Market Revenue and Forecast (2021-2034)
9.1.6. Neurology
9.1.6.1. Market Revenue and Forecast (2021-2034)
9.1.7. Cardiovascular
9.1.7.1. Market Revenue and Forecast (2021-2034)
9.1.8. Lifestyle and Endocrinology
9.1.8.1. Market Revenue and Forecast (2021-2034)
9.1.9. Gastroenterology
9.1.9.1. Market Revenue and Forecast (2021-2034)
9.1.10. Others
9.1.10.1. Market Revenue and Forecast (2021-2034)
Chapter 10. Global Non-Oncology Precision Medicine Market, By End-use
10.1. Non-Oncology Precision Medicine Market, by End-use, 2023-2032
10.1.1. Hospitals
10.1.1.1. Market Revenue and Forecast (2021-2034)
10.1.2. Diagnostic Centers
10.1.2.1. Market Revenue and Forecast (2021-2034)
10.1.3. Research & Academic Institutes
10.1.3.1. Market Revenue and Forecast (2021-2034)
10.1.4. Others
10.1.4.1. Market Revenue and Forecast (2021-2034)
Chapter 11. Global Non-Oncology Precision Medicine Market, By Ecosystem
11.1. Non-Oncology Precision Medicine Market, by Ecosystem, 2023-2032
11.1.1. Applied Sciences
11.1.1.1. Market Revenue and Forecast (2021-2034)
11.1.2. Precision Diagnostics
11.1.2.1. Market Revenue and Forecast (2021-2034)
11.1.3. Digital Health and Information Technology
11.1.3.1. Market Revenue and Forecast (2021-2034)
11.1.4. Precision Therapeutics
11.1.4.1. Market Revenue and Forecast (2021-2034)
Chapter 12. Global Non-Oncology Precision Medicine Market, Regional Estimates and Trend Forecast
12.1. North America
12.1.1. Market Revenue and Forecast, by Product Type (2021-2034)
12.1.2. Market Revenue and Forecast, by Application (2021-2034)
12.1.3. Market Revenue and Forecast, by End-use (2021-2034)
12.1.4. Market Revenue and Forecast, by Ecosystem (2021-2034)
12.1.5. U.S.
12.1.5.1. Market Revenue and Forecast, by Product Type (2021-2034)
12.1.5.2. Market Revenue and Forecast, by Application (2021-2034)
12.1.5.3. Market Revenue and Forecast, by End-use (2021-2034)
12.1.5.4. Market Revenue and Forecast, by Ecosystem (2021-2034)
12.1.6. Rest of North America
12.1.6.1. Market Revenue and Forecast, by Product Type (2021-2034)
12.1.6.2. Market Revenue and Forecast, by Application (2021-2034)
12.1.6.3. Market Revenue and Forecast, by End-use (2021-2034)
12.1.6.4. Market Revenue and Forecast, by Ecosystem (2021-2034)
12.2. Europe
12.2.1. Market Revenue and Forecast, by Product Type (2021-2034)
12.2.2. Market Revenue and Forecast, by Application (2021-2034)
12.2.3. Market Revenue and Forecast, by End-use (2021-2034)
12.2.4. Market Revenue and Forecast, by Ecosystem (2021-2034)
12.2.5. UK
12.2.5.1. Market Revenue and Forecast, by Product Type (2021-2034)
12.2.5.2. Market Revenue and Forecast, by Application (2021-2034)
12.2.5.3. Market Revenue and Forecast, by End-use (2021-2034)
12.2.5.4. Market Revenue and Forecast, by Ecosystem (2021-2034)
12.2.6. Germany
12.2.6.1. Market Revenue and Forecast, by Product Type (2021-2034)
12.2.6.2. Market Revenue and Forecast, by Application (2021-2034)
12.2.6.3. Market Revenue and Forecast, by End-use (2021-2034)
12.2.6.4. Market Revenue and Forecast, by Ecosystem (2021-2034)
12.2.7. France
12.2.7.1. Market Revenue and Forecast, by Product Type (2021-2034)
12.2.7.2. Market Revenue and Forecast, by Application (2021-2034)
12.2.7.3. Market Revenue and Forecast, by End-use (2021-2034)
12.2.7.4. Market Revenue and Forecast, by Ecosystem (2021-2034)
12.2.8. Rest of Europe
12.2.8.1. Market Revenue and Forecast, by Product Type (2021-2034)
12.2.8.2. Market Revenue and Forecast, by Application (2021-2034)
12.2.8.3. Market Revenue and Forecast, by End-use (2021-2034)
12.2.8.4. Market Revenue and Forecast, by Ecosystem (2021-2034)
12.3. APAC
12.3.1. Market Revenue and Forecast, by Product Type (2021-2034)
12.3.2. Market Revenue and Forecast, by Application (2021-2034)
12.3.3. Market Revenue and Forecast, by End-use (2021-2034)
12.3.4. Market Revenue and Forecast, by Ecosystem (2021-2034)
12.3.5. India
12.3.5.1. Market Revenue and Forecast, by Product Type (2021-2034)
12.3.5.2. Market Revenue and Forecast, by Application (2021-2034)
12.3.5.3. Market Revenue and Forecast, by End-use (2021-2034)
12.3.5.4. Market Revenue and Forecast, by Ecosystem (2021-2034)
12.3.6. China
12.3.6.1. Market Revenue and Forecast, by Product Type (2021-2034)
12.3.6.2. Market Revenue and Forecast, by Application (2021-2034)
12.3.6.3. Market Revenue and Forecast, by End-use (2021-2034)
12.3.6.4. Market Revenue and Forecast, by Ecosystem (2021-2034)
12.3.7. Japan
12.3.7.1. Market Revenue and Forecast, by Product Type (2021-2034)
12.3.7.2. Market Revenue and Forecast, by Application (2021-2034)
12.3.7.3. Market Revenue and Forecast, by End-use (2021-2034)
12.3.7.4. Market Revenue and Forecast, by Ecosystem (2021-2034)
12.3.8. Rest of APAC
12.3.8.1. Market Revenue and Forecast, by Product Type (2021-2034)
12.3.8.2. Market Revenue and Forecast, by Application (2021-2034)
12.3.8.3. Market Revenue and Forecast, by End-use (2021-2034)
12.3.8.4. Market Revenue and Forecast, by Ecosystem (2021-2034)
12.4. MEA
12.4.1. Market Revenue and Forecast, by Product Type (2021-2034)
12.4.2. Market Revenue and Forecast, by Application (2021-2034)
12.4.3. Market Revenue and Forecast, by End-use (2021-2034)
12.4.4. Market Revenue and Forecast, by Ecosystem (2021-2034)
12.4.5. GCC
12.4.5.1. Market Revenue and Forecast, by Product Type (2021-2034)
12.4.5.2. Market Revenue and Forecast, by Application (2021-2034)
12.4.5.3. Market Revenue and Forecast, by End-use (2021-2034)
12.4.5.4. Market Revenue and Forecast, by Ecosystem (2021-2034)
12.4.6. North Africa
12.4.6.1. Market Revenue and Forecast, by Product Type (2021-2034)
12.4.6.2. Market Revenue and Forecast, by Application (2021-2034)
12.4.6.3. Market Revenue and Forecast, by End-use (2021-2034)
12.4.6.4. Market Revenue and Forecast, by Ecosystem (2021-2034)
12.4.7. South Africa
12.4.7.1. Market Revenue and Forecast, by Product Type (2021-2034)
12.4.7.2. Market Revenue and Forecast, by Application (2021-2034)
12.4.7.3. Market Revenue and Forecast, by End-use (2021-2034)
12.4.7.4. Market Revenue and Forecast, by Ecosystem (2021-2034)
12.4.8. Rest of MEA
12.4.8.1. Market Revenue and Forecast, by Product Type (2021-2034)
12.4.8.2. Market Revenue and Forecast, by Application (2021-2034)
12.4.8.3. Market Revenue and Forecast, by End-use (2021-2034)
12.4.8.4. Market Revenue and Forecast, by Ecosystem (2021-2034)
12.5. Latin America
12.5.1. Market Revenue and Forecast, by Product Type (2021-2034)
12.5.2. Market Revenue and Forecast, by Application (2021-2034)
12.5.3. Market Revenue and Forecast, by End-use (2021-2034)
12.5.4. Market Revenue and Forecast, by Ecosystem (2021-2034)
12.5.5. Brazil
12.5.5.1. Market Revenue and Forecast, by Product Type (2021-2034)
12.5.5.2. Market Revenue and Forecast, by Application (2021-2034)
12.5.5.3. Market Revenue and Forecast, by End-use (2021-2034)
12.5.5.4. Market Revenue and Forecast, by Ecosystem (2021-2034)
12.5.6. Rest of LATAM
12.5.6.1. Market Revenue and Forecast, by Product Type (2021-2034)
12.5.6.2. Market Revenue and Forecast, by Application (2021-2034)
12.5.6.3. Market Revenue and Forecast, by End-use (2021-2034)
12.5.6.4. Market Revenue and Forecast, by Ecosystem (2021-2034)
Chapter 13. Company Profiles
13.1. Pfizer Inc.
13.1.1. Company Overview
13.1.2. Product Offerings
13.1.3. Financial Performance
13.1.4. Recent Initiatives
13.2. Qiagen Inc.
13.2.1. Company Overview
13.2.2. Product Offerings
13.2.3. Financial Performance
13.2.4. Recent Initiatives
13.3. Quest Diagnostics Inc.
13.3.1. Company Overview
13.3.2. Product Offerings
13.3.3. Financial Performance
13.3.4. Recent Initiatives
13.4. Medtronic
13.4.1. Company Overview
13.4.2. Product Offerings
13.4.3. Financial Performance
13.4.4. Recent Initiatives
13.5. Novartis
13.5.1. Company Overview
13.5.2. Product Offerings
13.5.3. Financial Performance
13.5.4. Recent Initiatives
13.6. Laboratory Corporation of America Holdings
13.6.1. Company Overview
13.6.2. Product Offerings
13.6.3. Financial Performance
13.6.4. Recent Initiatives
13.7. bioMérieux SA
13.7.1. Company Overview
13.7.2. Product Offerings
13.7.3. Financial Performance
13.7.4. Recent Initiatives
13.8. Abbott Laboratories
13.8.1. Company Overview
13.8.2. Product Offerings
13.8.3. Financial Performance
13.8.4. Recent Initiatives
13.9. F. Hoffmann-La Roche A
13.9.1. Company Overview
13.9.2. Product Offerings
13.9.3. Financial Performance
13.9.4. Recent Initiatives
13.10. Eli Lilly & Company
13.10.1. Company Overview
13.10.2. Product Offerings
13.10.3. Financial Performance
13.10.4. Recent Initiatives
Chapter 14. Research Methodology
14.1. Primary Research
14.2. Secondary Research
14.3. Assumptions
Chapter 15. Appendix
15.1. About Us
15.2. Glossary of Terms
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client